Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fujisaki, Tomoaki | - |
dc.contributor.author | Ishikawa, Takayuki | - |
dc.contributor.author | Takamatsu, Hiroyuki | - |
dc.contributor.author | Suzuki, Kenshi | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Wang, Jianping | - |
dc.contributor.author | Carson, Robin | - |
dc.contributor.author | Crist, Wendy | - |
dc.contributor.author | Qi, Ming | - |
dc.contributor.author | Nagafuji, Koji | - |
dc.date.available | 2020-02-27T08:40:48Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-12 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/2939 | - |
dc.description.abstract | In the ALCYONE trial, daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) reduced the risk of disease progression or death by 50% versus bortezomib, melphalan, and prednisone (VMP) in patients with transplant-ineligible newly diagnosed multiple myeloma. Here, we report a subanalysis of East Asian patients from ALCYONE. After a median follow-up of 17.1 and 15.9 months for Japanese (n = 50) and Korean (n = 41) patients, respectively, median progression-free survival for D-VMP versus VMP was not reached (NR) versus 20.7 months in Japanese patients and NR versus 14.0 months in Korean patients. The overall response rate for D-VMP versus VMP was 96% versus 92% in Japanese patients and 91% versus 61% in Korean patients. Using next-generation sequencing, minimal residual disease negativity at 10(-5) sensitivity for D-VMP versus VMP was 33% versus 8% among Japanese patients and 17% versus 0% among Korean patients. Rates of any grade and grade 3/4 pneumonia were consistent with the rates observed for the global safety population. Similar efficacy and safety findings were observed in the combined Japanese and Korean subgroup and >= 75 years of age subgroup. In conclusion, D-VMP was safe and efficacious in East Asian patients, consistent with the global ALCYONE population. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.title | Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000490631100001 | - |
dc.identifier.doi | 10.1007/s00277-019-03794-9 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.98, no.12, pp.2805 - 2814 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85074613335 | - |
dc.citation.endPage | 2814 | - |
dc.citation.startPage | 2805 | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 98 | - |
dc.citation.number | 12 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article; Early Access | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.subject.keywordAuthor | Daratumumab | - |
dc.subject.keywordAuthor | VMP | - |
dc.subject.keywordAuthor | Transplant-ineligible | - |
dc.subject.keywordPlus | ANTIBODY DARATUMUMAB | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | TARGETING CD38 | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.